Keymed Biosciences Inc - ESG Rating & Company Profile powered by AI
This report of Keymed Biosciences Inc is assembled by All Street Sevva using proprietary NLP. This assessment of Keymed Biosciences Inc uses data points from across the internet as well as from public disclosures by Keymed Biosciences Inc. The webpage includes a questions and answers table on Keymed Biosciences Inc.
Keymed Biosciences Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 6.7, social score of 5.7 and governance score of 2.7.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
60 | Aethlon Medical Inc | 5.2 | High |
62 | HBM Healthcare Investments AG | 5.1 | High |
63 | Keymed Biosciences Inc | 5.0 | High |
63 | Nightingale Health Oyj | 5.0 | High |
65 | AVRA Medical Robotics Inc | 4.9 | High |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Keymed Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Keymed Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes Keymed Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Keymed Biosciences Inc offer flexible work?
Sign up for free to unlockDoes Keymed Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Keymed Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Keymed Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes Keymed Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Keymed Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Keymed Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Keymed Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Keymed Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Keymed Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Keymed Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes Keymed Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes Keymed Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Keymed Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Keymed Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.